General Hospital Of Nea Ionia Konstantopouleio Patision

The Cardiology Department at General Hospital Of Nea Ionia Konstantopouleio Patision concentrates on preventing and treating atherosclerotic cardiovascular disease. Researchers are testing innovative approaches to lower the risk of heart attacks and strokes in patients without prior events.

• Evaluation of monoclonal antibodies targeting inflammatory pathways
• Assessment of new lipid‑lowering agents in high‑risk populations
• Long‑term safety studies of cardiovascular outcome drugs

With 24 active studies and a team of eight investigators, the site contributes valuable data to global cardiovascular research.

Ongoing trials address heart failure with preserved or reduced ejection fraction and its interaction with obesity, kidney disease, and systemic inflammation. The goal is to improve survival and quality of life for patients with complex comorbidities.

• Comparison of combined SGLT2 inhibitor regimens versus standard therapy
• Investigation of IL‑6 inhibition on heart failure symptoms and physical function
• Testing novel agents in patients with HFpEF, obesity, and metabolic dysfunction

These studies reflect the department’s commitment to integrating metabolic and inflammatory insights into heart failure care.

The site explores innovative strategies for atrial fibrillation, focusing on rapid restoration of sinus rhythm and safe anticoagulation alternatives for patients unsuitable for oral agents.

• Intravenous flecainide with oral ranolazine versus flecainide alone
• Evaluation of a novel anti‑Xa antibody for urgent reversal of anticoagulation
• Head‑to‑head trial of flecainide versus amiodarone in emergency cardioversion

By enrolling patients directly from emergency departments, the research aims to shorten time to rhythm control and reduce complications.

Researchers are assessing cutting‑edge treatments that target lipoprotein(a) and LDL cholesterol to cut cardiovascular risk in individuals with elevated levels despite optimal standard care.

• Large‑scale evaluation of a potent Lp(a)‑lowering antisense drug
• Assessment of PCSK9 inhibition on coronary events in high‑risk adults
• Long‑term safety follow‑up of participants completing Lp(a) studies

These investigations support personalized lipid management strategies for patients with persistent atherogenic risk.

The department conducts trials on rapid reversal of direct oral anticoagulants and prevention of postoperative venous thromboembolism, addressing urgent clinical scenarios.

• Comparison of a novel reversal agent with standard four‑factor PCC
• Single‑day dosing study of an investigational antibiotic for hospital‑acquired pneumonia
• Evaluation of an oral agent versus aspirin for VTE prophylaxis after knee replacement

Findings aim to improve safety for patients requiring urgent surgery while on anticoagulant therapy.

In addition to cardiovascular work, the site investigates treatments for chronic pruritic skin conditions, such as prurigo nodularis and lichen simplex chronicus, focusing on patient‑reported outcomes.

• Efficacy of a targeted monoclonal antibody on itch severity
• Assessment of dupilumab for refractory lichen simplex chronicus
• Quality‑of‑life measurement in dermatology trials

These studies broaden the hospital’s research portfolio beyond traditional cardiac indications.

A focused trial examines therapeutic transition strategies for patients with well‑controlled recurrent pericarditis, seeking to maintain remission while simplifying treatment regimens.

• Dosing regimen optimization for a novel pericarditis agent
• Long‑term efficacy monitoring of the new therapy
• Safety profiling in a population with prior standard‑of‑care exposure

This work highlights the department’s dedication to addressing uncommon yet impactful cardiac inflammatory diseases.